Carvedilol Use in Heart Failure

Sackner-Bernstein JD Mancini DM . Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995;274: 1462–7.

Ertl G Neubauer S Gaudron P Horn M Hu K Tian R Beta-blockers in cardiac failure. Eur Heart J 1994;15:16–24.

Ruffolo RR Boyle DA Brooks DP Feuerstein GZ Venuti RP Lukas MA Carvedilol: A novel cardiovascular drug with multiple actions. Cardiovasc Drug Rev 1992;10:127–57.

Louis WJ Krum H Conway EL . A risk—benefit assessment of carvedilol in the treatment of cardiovascular disorders. Drug Saf 1994;11:86–93.

Das Gupta P Broadhurst P Raferty EB Lahiri A . Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118–23.

Krum H Sackner-Bernstein JD Goldsmith RL Kukin ML Schwartz B Penn J Double-blind, placebo-controlled study of the long term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499–506.

Olsen SL Gilbert EM Renlund DG Taylor DO Yanowitz FD Bristow MR . Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol 1995;25:1225–31.

Australia—New Zealand Heart Failure Collaborative Group. Effects of carvedilol, a vasodilator—beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212–8.

Australia/New Zealand Heart Failure Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375–80.

Bristow MR Gilbert EM Abraham WT Adams KF Fowler MB Hershberger RE Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807–16.

Colucci WS Packer M Bristow MR Gilbert EM Cohn JN Fowler MB Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800–6.

Packer M Colucci WS Sackner-Bernstein JD Liang C Goldscher DA Freeman I Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996;94:2793–9.

Packer M Bristow MR Cohn JN Colucci WS Fowler MB Gilbert EM The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–55.

Karpman HL . Carvedilol — Are beta-blockers good for CHF (commentary)? Intern Med Alert 1996;18:116–7.

Norman GR Streiner DL , eds. Biostatistics: the bare essentials. St. Louis: Mosby, 1994:15.

Packer M Cohn JN Colucci WS . Carvedilol in patients with chronic heart failure (letter). N Engl J Med 1996;335:1319–20.

SmithKline Beecham Coreg approved to “reduce the progression” of congestive heart failure; label discusses secondary endpoints, including quality of life. F-D-C Rep 1997;59(22):3–4.

Waagstein F Bristow MR Swedberg K Camerini F Fowler MB Silver MA Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441–6.

CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765–73.

Leung WH Lau CP Wong CK Cheng CH Tai YT Lim SP . Improvement in exercise performance and hemodynamics by labetalol in patients with idiopathic dilated cardiomyopathy. Am Heart J 1990;119:884–90.

BEST Steering Committee. Design of the Beta-blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995;75:1220–3.

Fleming TR DeMets DL . Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996;125:605–13.

Fleming TR . Surrogate endpoints in clinical trials. Drug Inf J 1996;30: 545–51.

ACC/AHA Task Force Report. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on evaluation and management of heart failure). J Am Coll Cardiol 1995;26:1376–98.